CEA BASED VACCINE THERAPY OF CEA BEARING TUMORS

申请人的描述（Applicant's Description） 本提案中的工作将建立在我们早期的翻译经验基础上 在癌症疫苗治疗中，希望能改善临床 结果超过了最初的人体试验，以扩大我们的证据， 癌症疫苗疗法能够刺激免疫系统， 识别并杀死人体内的癌细胞，并更好地了解如何最好地 来监测癌症患者的免疫反应。 具体目标是： (1)以确定最佳的管理方案的基础上，提高 两种CEA靶向疫苗的T细胞活性，以产生增强的免疫应答。 CEA携带癌症患者的抗肿瘤免疫应答;（2） 确定GM-CSF和/或IL-2在进一步增强T细胞免疫应答中的作用， 接种CEA靶向疫苗后的免疫应答 携带CEA的癌症患者;（3）确定肿瘤负荷是否 在患者对这两种CEA靶向的免疫应答中起作用 通过比较患者的T细胞反应， （4）对那些有放射学证据的疾病进行记录， 在晚期癌症患者中具有抗肿瘤活性的任何证据， 确定响应之间是否存在相关性（如果看到响应） 和免疫增强的程度。

DESCRIPTION (Applicant's Description) The work in this proposal will build on our early translational experience in cancer vaccine therapeutics in the hopes of improving the clinical results over those from the initial human trial, to expand our evidence that cancer vaccine therapies are able to stimulate the immune system to recognize and kill cancer cells in humans, and to better understand how best to monitor the immune response in cancer patients. The specific aims are: (1) to determine the optimum administration schedule based on enhancement of T-cell activity of two CEA-targeting vaccines to generate an enhanced anti-tumor immune response in patients with CEA-bearing cancers; (2) to determine the role of GM-CSF and/or IL-2 in further enhancing the T-cell immune response following vaccination with CEA-targeting vaccines in patients with CEA-bearing cancers; (3) to determine whether tumor burden plays a role in a patient's immunologic response to these two CEA-targeting vaccines by comparing the T-cell response of patients without evidence of disease to those with radiographically evident disease, and (4) to document any evidence of anti-tumor activity in patients with advanced cancer and determine if a correlation exists between response (if responses are seen) and degree of immunologic enhancement.